Japan’s AGC Makes Agreed €240m Bid For MolMed

Silvio Berlusconi’s Fininvest holds 23% in the cancer-focused biotech

 
• By Sten Stovall
  
M&A
AGC wants to catch clinical-stage Italian biotech MolMed • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip